← United States · Coverage record
US · SEC FORM 4
Adicet Bio, Inc.
ACET · Nasdaq · CIK 0001720580 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
1 Form 4 transaction lines observed in the same window
0 sales · 1 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-10-08 · ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP V LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC; OrbiMed Israel BioFund GP Limited Partnership; OrbiMed Israel GP II, L.P.; OrbiMed Israel GP Ltd..
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- -29.8%
- 3M
- -28.3%
- 6M
- -7.0%
- 12M
- —
Volatility & liquidity
- Volatility
- 79.7%
- Beta
- 1.59
- Avg daily value
- USD 1.1M
Valuation
- Market cap
- USD 60.8M
- P/E
- —
Fundamentals
- Profit margin
- 0.0%
- ROE
- -73.4%
- Industry
- Biotechnology
Market data
Price data up to: 2026-10-04 · Price source: OpenBB/yfinance · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · From Yahoo Finance: Market cap, Profit margin · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 485,466
- Previous report
- 271,989
- Avg daily volume
- 439,513
- Days to cover
- 1.1
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-10-08 | ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP V LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC; OrbiMed Israel BioFund GP Limited Partnership; OrbiMed Israel GP II, L.P.; OrbiMed Israel GP Ltd. | Purchase (P) | Common Stock | 5,000,000 | USD 1.00 | USD 5,000,000 | SEC filing ↗ |
| 2024-01-25 | ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP V LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC; OrbiMed Israel BioFund GP Limited Partnership; OrbiMed Israel GP II, L.P.; OrbiMed Israel GP Ltd. | Purchase (P) | Common Stock | 3,125,000 | USD 2.40 | USD 7,500,000 | SEC filing ↗ |
| 2024-01-25 | GORDON CARL L | Purchase (P) | Common Stock | 3,125,000 | USD 2.40 | USD 7,500,000 | SEC filing ↗ |
| 2023-10-02 | Schor Chen | Purchase (P) | Common Stock | 5,500 | USD 1.33 | USD 7,315 | SEC filing ↗ |
| 2023-09-28 | Schor Chen | Purchase (P) | Common Stock | 5,500 | USD 1.42 | USD 7,810 | SEC filing ↗ |
| 2023-06-30 | DUBIN STEVE | Purchase (P) | Common Stock | 5,000 | USD 2.40 | USD 12,000 | SEC filing ↗ |
| 2023-06-27 | GORDON CARL L | Purchase (P) | Common Stock | 875,000 | USD 2.09 | USD 1,828,750 | SEC filing ↗ |
| 2023-06-27 | Chimovits Erez; ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP V LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC; OrbiMed Israel BioFund GP Limited Partnership; OrbiMed Israel GP II, L.P.; OrbiMed Israel GP Ltd. | Purchase (P) | Common Stock | 875,000 | USD 2.09 | USD 1,828,750 | SEC filing ↗ |
| 2021-12-08 | Sinclair Andrew | Purchase (P) | Common Stock | 500,000 | USD 14.00 | USD 7,000,000 | SEC filing ↗ |
| 2021-12-08 | Sinclair Andrew | Purchase (P) | Common Stock | 500,000 | USD 14.00 | USD 7,000,000 | SEC filing ↗ |
Form 4 evidence
9 transaction lines in the latest 365-day window; 226 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-04-27 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | J (J) | Common Stock | 250,000 | USD — | USD — | SEC filing ↗ |
| 2026-04-08 | ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP V LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC; OrbiMed Israel BioFund GP Limited Partnership; OrbiMed Israel GP II, L.P.; OrbiMed Israel GP Ltd. | Sale (S) | Common Stock | 72,939 | USD 6.42 | USD 468,082 | SEC filing ↗ |
| 2026-04-07 | ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP V LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC; OrbiMed Israel BioFund GP Limited Partnership; OrbiMed Israel GP II, L.P.; OrbiMed Israel GP Ltd. | Sale (S) | Common Stock | 31,719 | USD 6.52 | USD 206,765 | SEC filing ↗ |
Show recent Form 4 evidence (7 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-04-27 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | J (J) | Common Stock | 250,000 | USD — | USD — | SEC filing ↗ |
| 2026-04-08 | ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP V LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC; OrbiMed Israel BioFund GP Limited Partnership; OrbiMed Israel GP II, L.P.; OrbiMed Israel GP Ltd. | Sale (S) | Common Stock | 72,939 | USD 6.42 | USD 468,082 | SEC filing ↗ |
| 2026-04-07 | ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP V LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC; OrbiMed Israel BioFund GP Limited Partnership; OrbiMed Israel GP II, L.P.; OrbiMed Israel GP Ltd. | Sale (S) | Common Stock | 31,719 | USD 6.52 | USD 206,765 | SEC filing ↗ |
| 2026-01-24 | Schor Chen | Tax withholding (F) | Common Stock | 1,755 | USD 8.44 | USD 14,812 | SEC filing ↗ |
| 2026-01-24 | Healey Don | Tax withholding (F) | Common Stock | 535 | USD 8.44 | USD 4,515 | SEC filing ↗ |
| 2026-01-24 | Harvey Brian Nicholas | Tax withholding (F) | Common Stock | 546 | USD 8.44 | USD 4,608 | SEC filing ↗ |
| 2026-01-24 | Aftab Blake | Tax withholding (F) | Common Stock | 535 | USD 8.44 | USD 4,515 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | ACET |
| CIK | 0001720580 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 226 transaction lines from 2020-09-15 to 2026-04-27 21 P purchase lines · 73 S sale lines · 132 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.